Nearly a year after the FDA approved the first brain imaging test to diagnose Alzheimer’s, the test remains uncommon outside of research trials. “We have a lot of interest, but few patients are willing to pay for it,” notes Judith Rose, MD, director of PET/CT and nuclear medicine for RadNet.